Dificid, Dificlir, fidaxomicin (OPT-80)

Also known as: formerly difimicin, PAR-101

General Information

Company	Optimer Pharmaceuticals Inc.
Description	Macrocyclic narrow-spectrum antibiotic
Molecular Target	Not available
Mechanism of Action	Polymerase inhibitor

Latest Stage of Development	Marketed
Indication	Clostridium
Partner	Astellas Pharma Inc.; AstraZeneca plc; Cubist Pharmaceuticals Inc.; OBI Pharma Inc.; Specialised Therapeutics Australia Pty. Ltd.

Product Details

Archive Items are loading